Highest-materiality recent filing
Lantern Pharma Q2 net loss $7.1M; LP-300 PFS benefit deepens; OMAI spin-off
Q2 2026 net loss $7.1M ($0.57/share) vs $4.3M ($0.40) YoY; operating loss down 25% to $3.5M.
Lantern Pharma spins out AI platform as Open-Medicine AI, signs commercial licenses
Lantern Pharma (LTRN) creates Open-Medicine AI as a separate company to commercialize its multi-agent AI co-scientist platform.
Lantern Pharma uses presentation to discuss Harmonic Phase 2 trial of LP-300
Presentation furnished as Exhibit 99.1 on June 1, 2026, regarding LP-300 in Harmonic Phase 2 trial.
Net loss of $3.3M ($0.30/sh) vs $4.5M ($0.42/sh) in Q1 2025, a 27% reduction.
Lantern Pharma raises $4.4M through registered direct offering; plans to spin out AI platform
Offered 2,135,923 shares at $2.06/share (or pre-funded warrants) plus unregistered warrants for equal shares.
Lantern Pharma demonstrates withZeta.ai AI co-scientist platform; no financial data disclosed
Live demo of withZeta.ai, a multi-agentic AI platform for rare cancer drug discovery and clinical design.
Lantern Pharma FY2025 net loss narrows to $17.1M; cash runway into mid-2026; pipeline advances
Cash and marketable securities $10.1M as of Dec 31, 2025, down from $24.0M; expects funding needs by late Jul–mid Sep 2026.
Lantern Pharma demonstrates AI tools for rare cancers at Jan 22 event
Event hosted on Jan 22, 2026 to showcase initial AI tools and multi-agentic system for rare cancers.
Lantern Pharma Q3 net loss $4.2M; LP-184 Phase 1a achieves 48% clinical benefit rate
Net loss $4.2M ($0.39/shr) vs $4.5M loss in Q3 2024; cash $12.4M, runway into Q3 2026.
All six director nominees elected: Keyser (2.21M for), Sharma (2.21M), Chandru (2.20M), Maccecchini (2.21M), Schalop (2.21M), Silberstein (2.21M); broker non-votes 5.19M.
Q2 2025 net loss $4.33M ($0.40/share) vs $4.96M ($0.46) a year ago; cash $15.9M as of June 30, 2025.
Lantern Pharma appoints Lee T. Schalop to Board, reduces shareholder quorum to 33.33%
Appointed Lee T. Schalop, M.D., former CEO of Oncoceutics (sold to Chimerix for $450M), to the Board effective July 24, 2025.
Lantern Pharma enters $15.53M ATM equity offering agreement with ThinkEquity
ATM Sales Agreement allows sale of up to $15,530,000 in common stock through ThinkEquity as agent.
Lantern Pharma Q1 net loss $4.5M; LP-184 Phase 1a enrollment to complete by June 2025
Cash and equivalents $19.7M as of Mar 31, 2025, down from $24.0M at Dec 31, 2024.
Lantern Pharma reports Q4 2024 net loss $5.9M ($0.54/share); cash $24M as pipeline advances
Net loss for Q4 2024 was $5.9M ($0.54 per share) vs $4.2M ($0.39) in Q4 2023; full year net loss $1.93/share vs $1.47.
Lantern Pharma amends CSO Bhatia's agreement: term to Jan 2026, reduced hours, $189,600 salary
Kishor G. Bhatia, CSO, employment term extended to January 15, 2026.
Lantern Pharma Q3 2024 earnings call held; no financial details in 8-K
Conference call and live webinar occurred on November 7, 2024 for Q3 results.
Lantern Pharma Q3 net loss $4.5M; LP-300 shows 86% clinical benefit rate in lead-in
Net loss of $4.5M ($0.42/share) vs $3.2M ($0.29/share) in Q3 2023; cash & securities $28.1M.
Lantern Pharma Q2 net loss $4.96M; LP-300 Harmonic trial 86% CBR
Net loss of $4.96M ($0.46/shr) for Q2 2024 vs $4.75M ($0.44/shr) a year ago; cash $33.3M at June 30.
Stockholders approve all proposals at 2024 annual meeting
Five directors elected: Keyser, Sharma, Chandru, Maccecchini, Silberstein; each received ~3.04M votes for, ~22K withheld.
Lantern Pharma amends bylaws to streamline director count setting
Board of Directors approved amendment to Section 3.02 of Bylaws on May 23, 2024, effective immediately.
Lantern Pharma Q1 2024 net loss $5.4M, cash $38.4M; clinical trials advance
Net loss $5.4M ($0.51/share) vs $3.9M ($0.36/share) in Q1 2023; R&D expense $4.3M vs $2.6M.
Lantern Pharma reports Q4 2023 net loss $4.2M; cash $41.3M; clinical programs advance
Net loss Q4 2023 $4.2M ($0.39/sh) vs $3.4M ($0.31/sh) Q4 2022; full-year loss $1.47/sh.
Lantern Pharma raises CSO and CFO salaries and bonus targets effective Jan 1, 2024
CSO Kishor Bhatia base salary increased to $316,000; target bonus set at 40% of base.
Lantern Pharma to repurchase 145K shares from Bios Entities at $3.44/share
Company agreed to buy 145,348 common shares from Bios Fund I entities at $3.44/share, total ~$500K.
Net loss $3.2M ($0.29/shr) vs $2.3M ($0.21/shr) in Q3 2022; R&D rose to $2.2M from $0.7M due to prior-year one-time payment.
Lantern Pharma announces unexpected death of director Dr. Franklyn Prendergast
Dr. Franklyn Prendergast died unexpectedly; company learned on October 17, 2023.
Lantern Pharma Q2 2023 net loss $4.7M; cash $48.0M; LP-184 IND cleared, LP-284 IND imminent
Cash and equivalents $48.0M at June 30, 2023 ($55.2M at Dec 2022); cash runway into 2025.
Lantern Pharma shareholders elect directors, approve 250K share increase, ratify auditor
All six director nominees elected: Donald Jeff Keyser, Panna Sharma, Vijay Chandru, Maria Maccecchini, Franklyn Prendergast, David S. Silberstein.
Lantern Pharma Q1 net loss $3.9M; cash $51.5M; first patient dosed in Phase 2 Harmonic trial
Cash, cash equivalents, and marketable securities $51.5M as of March 31, 2023; cash runway into 2025.
Lantern Pharma reports FY2022 net loss $14.3M; cash $55.2M; IND timeline for LP-184/LP-284 in 2023
FY2022 net loss $14.3M ($1.31/sh) vs $12.4M ($1.13/sh) in FY2021; cash and equivalents $55.2M (Dec 31, 2022) down from $70.7M.
Lantern Pharma raises CSO Kishor Bhatia's base salary to $235,000 effective Jan 2023
Board approved amendment to employment agreement increasing annual base salary to $235,000.
Lantern Pharma Q3 2022 net loss improves to $2.3M; cash $57.8M, pipeline on track
Net loss of $2.3M ($0.21/shr) vs $4.1M ($0.36/shr) in Q3 2021; R&D expenses fell to $0.7M.
Lantern Pharma Q2 net loss $4.5M; launches Phase 2 Harmonic trial for LP-300 in never-smoker NSCLC
Net loss of $4.5M ($0.41 per share) vs $2.3M ($0.21) in Q2 2021; R&D spend increased to $3.0M from $1.2M.
Lantern Pharma shareholders elect six directors and ratify auditor at 2022 annual meeting
All six director nominees elected: Keyser, Sharma, Chandru, Maccecchini, Prendergast, Silberstein.
Lantern Pharma Q1 net loss $4.1M; cash $65.2M, RADR platform tops 20B data points
Cash and marketable securities $65.2M at March 31, 2022 vs $70.7M at Dec 31, 2021; net cash used $5.3M in Q1.
Lantern Pharma board nominee Maria Maccecchini; director Leslie Kreis not standing for reelection
Leslie W. Kreis, Jr. will not stand for reelection at the June 8, 2022 annual meeting.
Lantern Pharma provides disclosure channels reminder; no material news
Filing details company's website, press releases, SEC filings, newsletters, and social media as information channels.
Lantern Pharma extends share repurchase program to July 31, 2022; $3.6M remaining authorization.
Board extended existing share repurchase program through July 31, 2022, with $7M total authorization.
Lantern Pharma reports FY2021 net loss $12.4M; cash $70.7M; RADR platform surpasses 18B data points
Cash and marketable securities $70.7M at Dec 31, 2021, up from $19.2M at year-end 2020; share repurchase authorized up to $7M.
Lantern Pharma receives Rare Pediatric Disease and Orphan Drug designations for LP-184 in ATRT
FDA grants Rare Pediatric Disease Designation and Orphan Drug Designation for LP-184 to treat atypical teratoid rhabdoid tumor (ATRT).
Lantern Pharma announces $7M share repurchase program
Board authorized up to $7M of common stock repurchases.
Lantern Pharma Q3 net loss $4.05M, cash $73.8M; RADR hits 10B datapoints, LP-184 ODD
Net loss $4.05M ($0.36 per share) vs $1.70M in Q3 2020; R&D expenses $2.96M up from $0.60M.
Lantern Pharma reports Q2 2021 net loss $2.3M; cash $79.6M; positive LP-184 pancreatic data
Net loss $2.3M ($0.21/sh) vs $833K ($0.31/sh) in Q2 2020; R&D expenses rose to $1.16M.
On April 20, 2022, Leslie W. Kreis, Jr. notified Lantern Pharma Inc. (the “Company”) that he will not stand for reelection to the Company’s Board of Directors.
Max materiality 0.80 · Median 0.55 · Most common event earnings